MIST Milestone Pharmaceuticals

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston.

A live webcast of the fireside chat will be available to conference participants on March 4th at 9:10 AM EST. The webcast is available to watch both and replay for approximately 90-days following the presentation in the News & Events section of Milestone's website If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:

Kim Fox, Vice President, Communications,

Investor Relations

Chris Calabrese,

Kevin Gardner,



EN
27/02/2025

Underlying

MISTMilestone Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Milestone Pharmaceuticals

 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Of...

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A com...

17h / 12m 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces Proposed Public Offering MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares, accompanying Series A warrants to purchase common shares (the “Series A Warrants”) and accompanying Series B warrants to purchase common shares (the “Series B Warrants”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, accompa...

20h / 42m 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Re...

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigationa...

20h / 43m 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAM...

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in a...

June 16, 2025 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcar...

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference MONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the Jefferies Healthcare Conference, to take place June 3 - 5, 2025, in New York. A webcast of the presentation will be available on June 5th at 8:10 AM EDT. The webcast will be available to watch and there will be a replay for approximately 90-days following the presentation on ...

May 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch